Extracorporeal photopheresis: Clinical use so far

Journal of Clinical Apheresis

Volumn 27, Issue 3, 2012, Pages 126-131

  Sanford, Kimberly W ^a   Balogun, Rasheed A ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

apheresis; CTCL; ECP; extracorporeal; GVHD; lymphoma; photopheresis; plasma exchange

Indexed keywords

BEXAROTENE; CALCINEURIN INHIBITOR; CYCLOSPORIN; GLUCOCORTICOID; IMATINIB; IMMUNOMODULATING AGENT; INTERFERON; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PENTOSTATIN; PSORALEN; RETINOID; RITUXIMAB; SALICYLIC ACID DERIVATIVE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE GRAFT VERSUS HOST DISEASE; ASIA; BLOOD BUFFY COAT; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONFERENCE PAPER; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DISEASE SEVERITY; DRUG MEGADOSE; EUROPE; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; LEUKAPHERESIS; LEUKOCYTE; LOW ENERGY RADIATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; NEPHROGENIC SYSTEMIC FIBROSIS; PLACEBO EFFECT; PUVA; SEZARY SYNDROME; STEROID THERAPY; SYSTEMIC SCLEROSIS; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; UNITED STATES;

BRONCHIOLITIS OBLITERANS; CROHN DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; NEPHROGENIC FIBROSING DERMOPATHY; PHOTOPHERESIS; SCLERODERMA, SYSTEMIC;

EID: 84861792510     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21217     Document Type: Conference Paper

References (30)

1. Swerdlow SH, Campo E, Harris NL, Jaffee ES, Pilleri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid tissue, 4th ed. The International Agency for Research on Cancer. WHO Press Geneva Switzerland. 2008.
2. Gadenne AJ, Blanco R,. Mycosis fungoides: clinical presentations and diagnosis. J Geriatr Dermatol 1997; 5: 331-334.
3. Edelson R, Facktor M, Andrews A, Lutzner M, Schein P,. Successful management of the Sezary syndrome-mobilization and removal of extravascular neoplastic T cells by leukopheresis. N Engl J Med 1974; 291: 293-294.
4. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, McKiernan G, Christiansen I, Oster M, Honigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G, Laroche L,. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303.
5. Gottlieb SL, Wolfe JT, Fox FE, DeNardo BJ, Macey WH, Bromley PG, Lessin SR, Rook AH,. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10 year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-957.
6. Knobler R, Barr ML, Couriel DR, Ferrara JLM, French LE, Jaksch P, Reinisch W, Rook AH, Schwarz T, Greinix H,. Extrcorporeal photopheresis: past, present and future. J AM Acad Dermatol 2009; 61: 652-665.
7. Richardson SK, Lin JH, Vittorio CC, Kim EJ, Yoon JS, Junkins-Hopkins J, Rook AH,. High clinical response rate with multimodality immunomodulatory therapy for Sezary Syndrome. Clin Lymphoma Myeloma 2006; 7: 226-232.
8. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American society for apheresis. J Clin Apher 2010; 25: 83-177.
9. Reinisch W, Nahavandi H, Santella R, Zhang Y, Gasche C, Moser G, Waldhor T, Gangl A, Vogelsang H, Knobler R,. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Ailment Pharmacol Ther 2001; 15: 1313-1322.
10. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Oshsenkuhn T, Sanborn WJ, Parenti D, Lee K, Reinisch W,. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open label pilot study. Inflammatory Bowel Dis 2009: 15: 829-836.
11. Barnet AJ, Miller M, Littlejohn GO,. The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J 1998; 64: 121-125.
12. Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA, Rietschel RL, Wintroub B, Kahaleh MB, Varga J,. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 1992; 128: 337-346.
13. Knobler RM, French LE, Kim Y, et al. A randomized, double bind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2006; 54: 793-799.
14. Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema R, de Rie MA, Schellekens PT, ten Berge IJ, de Borgie CA, Bos JD,. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41: 915-922.
15. Ward DM,. Extracorporeal photopheresis: how, when and why. J Clin Apher 2011; 26: 276-285.
16. Mathur K, Morris S, Deighan C, Green R, Douglas KW,. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 2008; 23: 144-150.
17. McKenna KE, Whittaker S, Rhodes LE, Taylor P, Lloyd J, Ibbotson S, Russell-Jones R,. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British photodermatology group and the U. S. skin lymphoma group. British Association of Dermatologists. Br J Dermatol 2006; 154: 7-20.
18. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC,. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010; 45: 295-302.
19. Schmitz N, Eapen M, Horowitz MM, Zhange MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE,. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplant 2006; 108: 4288-4290.
20. Paczesny S, Choi SW, Ferrara LM,. Acute graft-versus-host disease: new treatment strategies. Current Opin Hematol 2009; 16: 427-436.
21. Perfetti P, Carlier P, Strada P, Gualandi F, Occhini D, Van Lint MT, Ibatici A, Lamparelli T, Bruno B, Raiola AM, Dominietto A, Di Grazia C, Bregante S, Zia S, Ferrari GM, Stura P, Pogliani E, Bacigalupo A,. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008; 42: 609-617.
22. Foss F, Roberts T, Miller K,. Novel pentostatin/extracorporeal photopheresis reduced intensity conditioning regimen: results in relapsed/refractory NHL (abstract) Blood 2002; 100: 112a.
23. Chan G, Foss F, Roberts T, et al. Decreased acute and chronic graft vs.host disease with early full donor engraftment following a pentostatin-based preparative regimen for allogeneic bone marrow transplantation in high risk patients (abstract) Blood 2001; 98: 383a.
24. Inamoto Y, Flowers MED,. Treatment of chronic graft-versus-host disease in 2011. Current opinion in hematology 2011; 18: 414-420.
25. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T,. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
26. Owsianowki M, Gollinick H, Siegert W, Schwerdtfeger R, Orfanos CE,. Successful treatment of chronic graft versus host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994; 14: 845-848.
27. Rosseti F, Dall'Amico R, Crovetti G, Messina C, Montini G, Dini G, Locatelli F, Argiolu F, Miniero R, Zacchello G,. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant 1996; 18 (Suppl 2): 175-181.
28. Kuzmina Z, Greinix HT, Knobler R, Worel N, Kouba M, Weigl R, Körmöczi U, Rottal A, Pohlreich D, Zielinski C, Pickl WF,. Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Blood 2009; 114: 744-746.
29. Yoshirhara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y, Tanosaki R, Mineishi S,. Lower incidence of bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005; 35: 1195-1200.
30. Garba F, Drillate P, Makowski C, Jacob MC, Richard MJ, Favrot M, Sotto JJ, Bensa JC, Cahn JY,. Extracoporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica 2005; 90: 1096-1101.